Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

3.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.2K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K
Classification of Skeletal Muscle Relaxants01:28

Classification of Skeletal Muscle Relaxants

3.2K
Skeletal muscle relaxants are a group of drugs that can reduce muscle stiffness and induce temporary paralysis to relieve pain. These agents can act centrally to reduce muscle tone or spasms in painful conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or spinal injuries; they are called antispasmodics or spasmolytics.
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
3.2K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

629
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
629

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis: a synopsis of MS-STAT2, a multicentre, randomised controlled, double-blind, phase 3 clinical trial.

Health technology assessment (Winchester, England)·2026
Same author

The clinical, radiological and genetic spectrum AARS2-related leukoencephalopathy: a case series of 15 patients and review of the literature.

Journal of neurology·2026
Same author

An automated quantitative report for multiple sclerosis using only 3D T2-fluid-attenuated inversion recovery MRI.

Neuroradiology·2026
Same author

Multi-arm multi-stage platform trials for neurological disease: accelerating progress.

Lancet (London, England)·2026
Same author

Increased functional network connectivity following cognitive rehabilitation in progressive multiple sclerosis with moderate to severe disabilty: findings from the CogEx study.

Journal of neurology·2026
Same author

Recalibration and external validation of vascular risk calculators for multiple sclerosis: A population-based study using CPRD data in England, 1987-2023.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

Premature ventricular complexes.

Clinical medicine (London, England)·2026
Same journal

Heart failure with preserved ejection fraction (HFpEF): diagnosis and management for the general physician.

Clinical medicine (London, England)·2026
Same journal

Trends and Widening Inequities in Cardiovascular-Kidney-Metabolic Involvement in Cardiovascular Mortality: A National Spatiotemporal Analysis, 2014-2023.

Clinical medicine (London, England)·2026
Same journal

Educating current and future healthcare professionals on evidence-based sustainable medicine.

Clinical medicine (London, England)·2026
Same journal

UK Foundation Programme training needs a national minimum standard for advanced life support.

Clinical medicine (London, England)·2026
Same journal

Prognostic value of left atrial diameter in chronic kidney disease: The KNOW-CKD study.

Clinical medicine (London, England)·2026
See all related articles

Related Experiment Video

Updated: Mar 10, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.9K

Multiple sclerosis, a treatable disease.

Anisha Doshi1, Jeremy Chataway2

  • 1University College London, London, UK anisha.doshi@ucl.ac.uk.

Clinical Medicine (London, England)
|December 14, 2016
PubMed
Summary
This summary is machine-generated.

This review covers multiple sclerosis (MS), a disabling neurological condition. It details MS diagnosis, subtypes, potential causes, and current treatments, emphasizing the need for new therapies for progressive MS.

Keywords:
Diagnostic criteriaepidemiologymultiple sclerosisprogressive multiple sclerosistreatments

More Related Videos

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

10.0K
Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin
08:57

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin

Published on: March 26, 2015

27.9K

Related Experiment Videos

Last Updated: Mar 10, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.9K
Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

10.0K
Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin
08:57

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin

Published on: March 26, 2015

27.9K

Area of Science:

  • Neurology
  • Immunology
  • Neuroscience

Background:

  • Multiple sclerosis (MS) is a chronic, disabling neurological disease with significant socioeconomic impact.
  • MS affects the central nervous system, leading to diverse clinical presentations.
  • Understanding MS etiology remains a challenge, though several factors are associated.

Purpose of the Study:

  • To review the current understanding of multiple sclerosis (MS).
  • To outline modern diagnostic criteria and subtypes of MS.
  • To summarize treatment strategies for MS, including acute relapses, disease-modifying therapies, and symptom management.

Main Methods:

  • Literature review of current understanding and treatment of MS.
  • Analysis of diagnostic criteria and classification of MS subtypes.
  • Summary of etiological associations and therapeutic approaches.

Main Results:

  • MS diagnosis relies on specific clinical and radiological features.
  • Key MS subtypes include clinically isolated syndrome, relapsing-remitting MS, secondary progressive MS, and primary progressive MS.
  • Current treatments address acute relapses and disease modification, with limited options for progressive MS.

Conclusions:

  • Effective management of MS involves early diagnosis and tailored treatment strategies.
  • Progressive MS represents a critical area requiring development of novel disease-modifying treatments.
  • Further research into MS etiology is essential for advancing therapeutic interventions.